Central centrifugal cicatricial alopecia (CCCA) is not classified as an autoimmune disease in the traditional sense, but it does involve an immune-driven inflammatory attack on hair follicles. The distinction matters: unlike autoimmune alopecia areata, where the immune system specifically targets healthy hair cells and the damage is often reversible, CCCA involves inflammation that permanently scars and destroys follicles. Most researchers now describe it as a scarring (cicatricial) alopecia with inflammatory and fibroproliferative features, meaning the damage comes from both immune activity and an abnormal wound-healing response that replaces hair follicles with scar tissue.
What Actually Happens to the Hair Follicle
In CCCA, hair loss begins at the crown of the scalp and spreads outward in a circular pattern. The process starts when the inner lining of the hair follicle breaks down prematurely, a finding pathologists call premature desquamation of the inner root sheath. Once this protective barrier fails, outside irritants like chemicals or bacteria can enter the follicle, triggering an inflammatory chain reaction.
Immune cells, primarily a type of white blood cell called lymphocytes, gather around the middle portion of the follicle and begin attacking it. Over time, thick bands of fibrous scar tissue replace the destroyed follicle entirely. This is what makes CCCA permanent: the stem cells that allow a hair follicle to regenerate itself are destroyed, and the follicle loses the ability to produce hair again. Under a microscope, affected follicles show a characteristic “onion skin” pattern of layered scarring around what’s left of the follicle structure.
How CCCA Differs From Autoimmune Hair Loss
Alopecia areata is the most well-known autoimmune form of hair loss. In that condition, the immune system mounts a highly targeted attack on the hair bulb (the deepest part of the follicle), producing a dense cluster of immune cells sometimes described as a “swarm of bees” pattern on biopsy. Critically, this attack doesn’t destroy the follicle’s stem cells, which is why hair can regrow once the immune flare calms down.
CCCA works differently. The inflammation centers on the upper and middle sections of the follicle, right where the stem cells live. The result isn’t just temporary hair loss but permanent destruction of the follicle’s regenerative machinery. And while the immune system plays a role in the damage, CCCA also involves an excessive scarring response that goes beyond what you’d see in a purely autoimmune process. Genes involved in tissue remodeling and fibrosis, including one that controls collagen production and another involved in growth signaling, are significantly overactive in CCCA-affected scalp tissue. This pattern closely mirrors what happens in other fibroproliferative disorders like keloid scars and uterine fibroids.
Genetics Play a Larger Role Than Expected
A 2019 study published in the New England Journal of Medicine identified mutations in a gene called PADI3, which produces a protein essential to normal hair shaft formation. Among the initial group of patients studied, 31% carried one of these mutations. The mutations reduced the protein’s activity and caused it to function abnormally inside cells, weakening the structural integrity of the hair shaft and follicle lining. This may explain why the inner root sheath breaks down prematurely in CCCA.
Family history reinforces the genetic connection. In a case-control study, 38.9% of CCCA patients reported a family history of hair loss, compared with just 14.8% of controls. Some families show an autosomal dominant inheritance pattern, meaning a single copy of an affected gene from one parent can be enough to increase risk. The genetic component may also explain why some patients respond poorly to standard treatments: their disease progression is driven more by an inherited structural vulnerability than by inflammation alone.
Who Gets CCCA
CCCA is the most common form of scarring alopecia overall, and it disproportionately affects Black women between the ages of 30 and 55. Prevalence estimates range from 2.7% to 5.6% of Black women, though the actual number may be higher since early-stage CCCA can be subtle and go undiagnosed for years.
Hair care practices appear to play a contributing role, though they likely don’t cause CCCA on their own. In one study, CCCA patients were far more likely than controls to use chemical relaxers (44.4% vs. 6.7%), high-tension hairstyles like tight braids or weaves (46.3% vs. 2.2%), and heated styling tools (14.8% vs. 3.0%). The current thinking is that these practices may accelerate damage in someone who already has a genetic predisposition, particularly if the inner root sheath is already compromised by a PADI3 mutation or similar structural weakness.
The Uterine Fibroid Connection
One of the more surprising findings in CCCA research is its link to uterine fibroids. A study published in JAMA Dermatology found that women with CCCA had nearly five times the odds of also having uterine fibroids compared to matched controls (13.9% vs. 3.3%). Both conditions involve excessive fibrosis, the same type of abnormal scar tissue buildup. This overlap supports the theory that CCCA is fundamentally a fibroproliferative condition rather than a classic autoimmune disease. In both CCCA and fibroids, the body’s wound-healing process essentially overreacts, depositing far more collagen and connective tissue than necessary.
What Treatment Looks Like
Because CCCA involves both inflammation and scarring, treatment targets both processes. The primary goal is stopping progression, since hair follicles that have already been replaced by scar tissue cannot be restored. Topical and injected anti-inflammatory medications are the mainstay, aimed at calming the immune activity around follicles that haven’t yet been destroyed. Some doctors also prescribe oral anti-inflammatory medications, including certain antibiotics used at low doses for their inflammation-reducing properties rather than their antimicrobial effects.
Early intervention makes a significant difference. In the active phase, when the scalp may feel tender, itchy, or show redness and flaking around the crown, there are still viable follicles to save. Once the disease burns out and the affected area is fully scarred, treatment options narrow considerably. For some patients with stable, long-standing CCCA, hair transplantation into the scarred area has been attempted, though results are less predictable than transplants for non-scarring hair loss. Reducing or eliminating chemical treatments and high-tension styles is generally recommended alongside medical therapy, particularly for patients with evidence of ongoing follicular damage.